News
TipRanks on MSN10d
Eli Lilly’s Stock (LLY) Is Upgraded by HSBC as Weight-Loss Pill Moves Closer to Approval
Rajesh Kumar, a top four-star rated analyst with a 62% success rate, raised his rating on LLY stock to Hold from Sell ...
Eli Lilly stock dropped more than 20% due to underwhelming results from its drug trials. However, a rebound may be underway.
On August 26, 2025, Eli Lilly announced positive topline results from its Phase 3 ATTAIN-2 trial of orforglipron, an ...
Eli Lilly's robust R&D, strong pipeline, and leadership in diabetes, obesity, and oncology underpin its long-term growth ...
Eli Lilly's orforglipron outshines Novo Nordisk's oral semaglutide with efficacy & scalability, promising growth in the ...
Eli Lilly’s LLY first-quarter revenue grew 45%, as combined sales for Mounjaro (diabetes) and Zepbound (obesity) rose dramatically to reach $6.2 billion, up year over year from $2.3 billion ...
TipRanks on MSN10d
Eli Lilly’s Promising Alzheimer’s Study: A Potential Game Changer?
Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback